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ABSTRACT 
 
The effects of spironolactone, a non-selective aldosterone antagonist, were examined on 
thermally-induced pain using the hot-plate and tail-flick tests, on chemogenic pain induced by 
intraplantar capsaicin, on electrically-induced pain, on visceral nociception induced by intra-
peritoneal acetic acid injection and on haloperidol-induced catalepsy in mice. Spironolactone 
significantly shortened response latency in the mouse tail-flick test but produced modest de-
creases in response latencies in the mouse hot plate test. The drug reduced the antinociceptive 
effect of tramadol in the hot plate test. Spironolactone in addition decreased nociceptive 
thresholds of electrically-induced pain in mice. In contrast, spironolactone elicited significant 
antinociceptive actions in the mouse acetic-acid-induced writhing assay and at doses of 20-
160 mg/kg decreased capsaicin-induced chemogenic pain. Spironolactone at doses of 40 or 
80 mg/kg reduced spontaneous activity and produced a significant impairment on the rotarod 
test in mice. The drug (10-80 mg/kg) increased the duration of catalepsy induced by haloperi-
dol by 56.3-188.5 %. In conclusion, spironolactone increased pain behavior in a dose-
dependent manner in models of thermal and electrical pain, but decreased inflammatory vis-
ceral pain due to intraperitoneal acetic acid and chemogenic pain due to intraplantar capsaicin. 
The effect of spironolactone on various types of pain needs further evaluation. 
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INTRODUCTION 
Spironolactone, a synthetic steroid with 
an aldosterone-like structure acts as non-
specific antagonist of aldosterone receptors. 
The drug is used for blocking aldosterone-
dependent sodium transport in the distal 
tubule of the kidney in order to reduce oe-
dema and to treat essential hypertension and 
primary hyperaldosteronism (Conn and 
Hinerman, 1977). Spironolactone is also 
used in the treatment of secondary hyperal-
dosteronism occurring in such conditions as 
liver cirrhosis and congestive heart failure 
(Mantero and Lucarelli, 2000; Tang et al., 
2005; Dib et al., 2006). The drug has in ad-
dition weak anti-androgenic action due to 
androgen receptor blockade (Carmina, 
2002) and recently has been demonstrated 
to possess anti-inflammatory and immune 
modifying properties (Francis et al., 2003; 
Hansen et al., 2004; Sonder et al., 2006).  
The mineralocorticoid receptor (MR) is 
mainly localized in the classical peripheral 
target tissues such as the kidney and in 
some areas within the brain (Krozowski and 
Funder, 1983; Geerling et al., 2006). In ad-
dition to their prime physiologic role in the 
control of electrolyte homeostasis and 
blood pressure, studies have shown that 
mineralocorticoid receptors (MRs) and glu-
cocorticoid receptors (GRs) are involved in 
the long-term corticosterone modulation of 
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the anxiety response induced by restraint 
(Calvo and Volosin, 2001), while forebrain 
mineralocorticoid receptor overexpression 
enhances memory, reduces anxiety and at-
tenuates neuronal loss in cerebral ischemia 
(Lai et al., 2007). Excessive stimulation of 
MRs in the brain increases sympathetic ex-
citation (Gomez-Sanchez, 1997). In the 
amygdala, MR–mediated mechanisms are 
likely to be involved in descending path-
ways onto lumbosacral spinal neurons that 
induce colorectal hypersensitivity to lu-
minal distension (Qin et al., 2003).  
The present study was designed to in-
vestigate for a possible pain modulating ef-
fect of aldosterone receptor blockade with 
spironolactone. In the present study, the ef-
fect of the non-selective aldosterone an-
tagonist, spironolactone, was evaluated in 
the acute nociceptive models of thermal, 
chemogenic, electrical and visceral pain in 
mice. The effect of spironolactone was in 
addition examined on haloperidol-induced 
catalepsy in mice, a model of Parkinsonism, 
caused about by D2 receptor blockade in 
the striatum (Farde et al., 1992; Hoffman 
and Donovan, 1995). 
 
MATERIALS AND METHODS 
 
Male Swiss albino mice (22-25 g) were 
used. Mice were housed under standardized 
conditions with free access to food and wa-
ter. Animal procedures were performed in 
accordance with the Ethics Committee of 
the National Research Centre and followed 
the recommendations of the National Insti-
tutes of Health Guide for Care and Use of 
Laboratory Animals (Publication No. 85-
23, revised 1985). Equal groups of 6 mice 
each were used in all experiments.  
 
Tail-flick assay 
The tail-flick test was used in mice to 
elicit a spinal tail flick response to noxious 
thermal stimuli. The test was performed 
with the tail-flick analgesia meter (Ugo 
Basile, Italy). Groups of mice (n=6/group) 
were given spironolactone (5, 10, 20, 40 or 
80 mg/kg, s.c., 0.2 ml) or saline (control). 
Each mouse was gently held with one hand 
and its tail positioned on the source of radi-
ant heat. The tail-flick response was elicited 
by applying radiant heat to the dorsal sur-
face of the tail. The time elapsed till the 
animal flicked its tail was determined. The 
test was done at 60 and 120 min after drug 
injection. 
 
Hot-plate assay 
The hot-plate test was performed using 
an electronically controlled hotplate (Ugo 
Basile, Italy) heated to 53 °C (± 0.1 °C). 
Each mouse was placed unrestrained on hot 
plate for the baseline measurement just 
prior to saline or drug administration. Dif-
ferent groups of mice (n=6/group) were 
given spironolactone (10, 20, 40 or 
80 mg/kg, s.c.) or saline (control). Meas-
urements were then taken 30 and 60 min 
after drug administration. Latency to lick a 
hind paw or jump out of the apparatus was 
recorded for the control and drug-treated 
groups. The cut-off time was 30s. In an-
other experiment, the effect of spironolac-
tone (40 or 80 mg/kg, s.c.) on antinocicep-
tion caused by tramadol (10 or 20 mg/kg, 
s.c.) was studied. Drugs were co-
administered 30 min prior to testing. 
 
Tail electric stimulation test  
Groups of mice (n=6/group) were given 
spironolactone (10, 20, 40 or 80 mg/kg, 
s.c.) or saline (control). The minimum cur-
rent required to elicit vocalization upon 
electrical stimulation of the tail was deter-
mined for the control and drug-treated 
groups (Michael-Titus and Costentin, 
1987). Electrical stimulation of the tail was 
applied by means of Pulse generator 57800-
001 (Ugo Basile EXT Unit) (Frequency 
50 pulse/sec, shock duration 2 sec). Spiro-
nolactone was administered 30 min prior to 
testing. 
 
Acetic acid-induced writhing 
Separate groups of 6 mice each were 
administered vehicle (saline) or spironolac-
tone 5, 10, 20, 40 or 80 mg/kg; 0.2 ml, 
orally. After 60 min of administration drug 
administration, an intraperitoneal (i.p.) in-
jection of 0.6 % acetic acid (0.2 ml) was 
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administered (Koster et al., 1959). In other 
experiments, the effect of the alpha-2 
adrenoceptor antagonist yohimbine 
(5 mg/kg, s.c.), the beta adrenoceptor an-
tagonist propranolol (2 mg/kg, s.c.), the 
adrenergic blocker guanethidine (16 mg/kg, 
s.c.), the muscarinic acetylcholine receptor 
antagonist atropine (1 mg/kg, s.c.) was ex-
amined on antinociception caused by spiro-
nolactone (10 mg/kg, s.c.). Drugs were ad-
ministered 30 min prior to acetic acid chal-
lenge. Furthermore, the effect of co-
administered spironolactone (40 or 
80 mg/kg, s.c.) and melatonin (4 mg/kg, 
i.p.) was examined. Drugs were adminis-
tered 30 min prior to the abdominal con-
striction assay. 
 
Capsaicin-induced hind paw licking  
Spironolactone (20, 40, 80 or 
160 mg/kg, s.c.) or saline was administered 
30 min before injection of capsaicin 
(1.6 µg/paw; 25 µl) under the skin of the 
dorsal surface of the right hind paw. Obser-
vation started after capsaicin injection and 
lasted for 5 min. The time the animals spent 
licking the injected paw was determined 
using a stopwatch (Sakurada et al., 1992).  
 
Rotarod testing 
Motor performance was measured as the 
latency to fall from an accelerating rotarod 
located over plates connected to an auto-
matic counter (Ugo Basile, Varese, Italy). 
Mice were trained to remain on a rotating 
rod for 2 min as the rod rotated toward the 
animal. After the 2-min training period, the 
mice were administered spironolactone (10, 
20, 40 or 80 mg/kg, i.p.) or saline (control) 
and 30 min later placed on the rotating rod 
as it accelerated from 4 to 40 rpm over 
5 min and the time that they could remain 
on the accelerating rod was noted (Millan et 
al., 1994). The cutoff time was 600 sec. The 
time was measured from the start of the ac-
celeration period.  
 
Haloperidol-induced catalepsy 
Catalepsy defined as a reduced ability to 
initiate movement and a failure to correct 
posture, was measured by the bar test. Mice 
were positioned so that their hindquarters 
were on the bench and their forelimbs 
rested on a 1 cm diameter horizontal bar, 
4 cm above the bench. The length of time 
the mouse maintained this position was re-
corded by a stopwatch to a maximum of 
180 s. This procedure was performed 
30 min after haloperidol (2 mg/kg, i.p.) ad-
ministration. Spironolactone (10, 20, 40 or 
80 mg/kg, i.p.) was co-administered with 
haloperidol. Mice were judged to be cata-
leptic if they maintained this position for 
30 s or more.  
 
Haloperidol-induced locomotor impair-
ment 
Mice were administered saline, haloper-
idol (2 mg/kg, i.p.) or haloperidol + spiro-
nolactone (10, 20, 40 or 80 mg/kg, i.p.). 
Thirty min after treatment with drugs or 
vehicle, mice were individually placed into 
a 40-cm3 activity monitor equipped with 
photoelectric detectors and the total number 
of horizontal beam interruptions (spontane-
ous locomotor activity) was counted over a 
6-min period for each animal.  
 
Statistical analysis 
Data are expressed as mean ± SE. Data 
were analyzed by one-way analysis of vari-
ance, followed by a Tukey's multiple range 
test for post hoc comparison of group 
means. When there were only two groups a 
two-tailed Student's t test was used. For all 
tests, effects with a probability of p<.05 
were considered to be significant. 
 
RESULTS 
 
Effect of spironolactone on thermal noci-
ception 
Spironolactone significantly and markedly 
shortened response latency in the mouse 
tail-flick test at all doses examined (5, 10, 
20, 40 or 80 mg/kg) by 41.4-54.8 % (Fig-
ure 1). Meanwhile, spironolactone at 
10 mg/kg did not affect response latency in 
the mouse hot plate test, but the drug at 20, 
40 or 80 mg/kg decreased hot plate laten-
cies 1h after drug administration by 26.5, 
31.9 and 16.6 %, respectively (Figure 2). 
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Figure 1: 1 h and 2 h values (first and second 
column, respectively) of tail flick latency (sec-
onds) of saline (control) and spironolactone-
treated mice. Each column represents mean ± 
SE of 6 mice/group.  
*p<0.05 compared to saline group at the corre-
sponding time 
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Figure 2: Basal (pre-drug), 30 min and 1 h val-
ues (first, second and third column, respec-
tively) of hot-plate latency (seconds) of saline 
(control) and spironolactone-treated mice. Each 
column represents mean ± SE of 6 mice/group. 
*p<0.05, **p<0.01 compared to its basal value  
 
Tramadol administered at 10 mg/kg, 
i.p., increased hot-plate latencies by 62.5, 
38.4 and 19.3 %, at 30 min, 1 h and 2 h af-
ter drug administration, respectively. 
Tramadol (10 mg/kg) co-administered with 
spironolactone at 40 or 80 mg/kg increased 
hot plate response latencies by 5.4, 30.2, 
and 29.7 % and by 4.3, 12.7, and 22.2 % at 
30 min, 1 h and 2 h post-drug, respectively. 
Tramadol administered at 20 mg/kg, i.p., 
increased hot-plate latencies by 68.4, 43.6 
and 23.5 %, 30 min, 1 h and 2 h after drug 
administration, respectively. Tramadol 
(20 mg/kg) co-administered with spiro-
nolactone at 40 mg/kg resulted in 55 and 
57 % increase in hot-plate latency, 30 min 
and 1 h post-drug, respectively. Tramadol 
(20 mg/kg) co-administered with spiro-
nolactone at 80 mg/kg caused 13.4, 31.9 
and 24.3 % increase in response latency in 
the hot-plate test, 30 min, 1 h and 2 h post-
drug (Figure 3). 
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Figure 3: Basal (pre-drug), 30 min, 1 h and 2 h 
values (first, second, third and fourth column, 
respectively) of hot-plate latency (seconds) of 
tramadol and tramadol + spironolactone-treated 
mice. Each column represents mean ± SE of 6 
mice/group.  
*p<0.05, **p<0.01 compared to its basal value 
 
 
Effect of spironolactone on tail electric 
stimulation  
Spironolactone (10, 20, 40 and 
80 mg/kg, i.p.) produced a dose-related de-
crease in electrical current threshold in the 
tail stimulation test in mice by 20.8, 21.5, 
37.5 and 54.2 % vs control values 1 h post-
drug, respectively (Table 1).  
 
 
 
EXCLI Journal 2010;9:46-57  ISSN 1611-2156 
Received: February 16, 2010, accepted: February 21, 2010, published: February 25, 2010 
 
50 
Table 1: Antinociceptive activity of spironolactone in the tail electric stimulation test in mice 
 
 Electric current threshold  
(microA) 
 
Drugs  % change 
Saline 480.0 ± 20.0  
Spironolactone   
10 mg/kg 380 ± 18.3 -20.8 
20 mg/kg 377 ± 16.1* -21.5 
40 mg/kg 300.0 ± 21.0* -37.5 
80 mg/kg 220.0 ± 20.0** -54.2 
 
Shown are control and drug-induced changes 
for the nociceptive reaction. Data are expressed 
as means ± SE (n=6/group). *Significant rise in 
electrical current threshold (microA) (p<0.05) 
compared with the saline control group (One-
way ANOVA, Duncan test) 
 
 
Effect of spironolactone on visceral noci-
ception 
Spironolactone administered via oral route 
produced a decrease in acetic acid-induced 
writhing in mice. It was noted that lower 
doses were more effective in reducing pain 
response. Spironolactone given at 5, 10, 20, 
40 or 80 mg/kg produced 52.3, 62.9, 50.8, 
33.5 and 32 % of the number of contrac-
tions induced by acetic acid (Figure 4). 
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Figure 4: Effect of orally administered spiro-
nolactone on the number of abdominal constric-
tions in the acetic acid-induced writhing assay 
in mice. Data represent mean values of 6 mice 
per group (± SE) and percent inhibition (%) 
compared to the control animals. Statistical dif-
ferences vs. control group are indicated by as-
terisks. 
 
The effect of spironolactone (10 mg/kg, 
s.c.) was unaffected by co-administration of 
atropine, propranolol or guanethidine, but 
yohimbine reduced the antinociceptive ef-
fect of spironolactone on the writhing re-
sponse (Figure 5). The effect of spironolac-
tone and melatonin was additive (Figure 6). 
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Figure 5: Effect of yohimbine, propranolol, at-
ropine and guanethidine on the antinociception 
caused by the administration of spironolactone 
(10 mg/kg. s.c.) in the acetic acid-induced writh-
ing assay in mice. Data represent mean values 
of 6 mice per group (± SE) and percent inhibi-
tion (%) compared to the control animals. Sta-
tistical differences vs. control group are indi-
cated by asterisks. The plus sign indicates sig-
nificant change from yohimbine + spironolac-
tone-treated group. 
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Figure 6: The effect of co-administered spiro-
nolactone (40 or 80 mg/kg, s.c.) and melatonin 
(4 mg/kg, i.p.) in the acetic acid-induced writh-
ing assay in mice. Drugs were administered 
30 min prior to the abdominal constriction as-
say. Data represent mean values of 6 mice per 
group (± SE) and percent inhibition (%) com-
pared to the control animals. Statistical differ-
ences vs. control group are indicated by aster-
isks. The plus sign indicates significant change 
from melatonin only-treated group. 
 
 
Effect of spironolactone on capsaicin-
induced paw licking 
The duration of paw licking following 
intraplantar capsaicin injection was de-
creased by 21.2, 75.9, 92.1 and 93.4 % fol-
lowing administration of 20, 40, 80 and 
160 mg/kg spironolactone, respectively 
(Figure 7). 
 
Rotarod testing 
Spironolactone administered at 10 or 
20 mg/kg did not affect rotarod perform-
ances compared to saline-treated mice (347 
± 22.6 vs. 342 ± 19.6 and 338 ± 26.0). Spi-
ronolactone administered at 40 or 80 mg/kg 
significantly impaired rotarod performances 
of the mice. Time spent on rotarod de-
creased from 347 ± 22.6 to 271.5 ± 18 and 
206 ± 12.2, respectively.  
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Figure 7: Effect of spironolactone on the dura-
tion of licking response to intraplantar capsaicin 
injection in mice. Data represent mean values 
(± SE) and percent inhibition (%) (Percent anal-
gesic effect) compared to the control animals. 
Statistical differences vs. control group are indi-
cated by asterisks. The plus sign indicates a 
significant change from the spironolactone 
20 mg/kg-treated group. The # sign indicates a 
significant change from the spironolactone 
40 mg/kg-treated group. 
 
 
Effect of spironolactone on the duration of 
haloperidol-induced catalepsy 
Haloperidol administered i.p. at a dose 
of 2 mg/kg produced a significant cataleptic 
response. The duration of haloperidol-
induced catalepsy was significantly in-
creased by 56.3, 89.4, 99.4 and 188.5 % by 
10, 20, 40 and 80 mg/kg of spironolactone, 
respectively (Figure 8). 
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Figure 8: Effect of spironolactone on haloperi-
dol-induced catalepsy in mice. Data represent 
mean values (± SE) of 6 mice per group and 
percent increase (%) compared to the control 
animals. Statistical differences vs. control group 
are indicated by asterisks. 
 
Effect of spironolactone on haloperidol-
induced locomotor impairment 
Spontaneous motor activity was mark-
edly and significantly reduced in haloperi-
dol-treated mice. Treatment with spiro-
nolactone resulted in further reduction in 
motor activity (Figure 9). 
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Figure 9: Effect of spironolactone on haloperidol-
induced motor impairment in mice. Data represent 
mean values (± SE) of 6 mice per group and percent 
inhibition (%) compared to the control animals. Sta-
tistical differences vs. control group are indicated by 
asterisks. 
DISCUSSION 
 
Results of the present study provide the 
evidence that the administration of spiro-
nolactone, a non-selective aldosterone an-
tagonist, have differing effects on acute no-
ciceptive pain. Thus in models of tail flick 
and hot plate in mice, which are measures 
of thermally-induced pain, the drug de-
creased nociceptive pain threshold. Spiro-
nolactone in addition decreased the antino-
ciceptive effect of tramadol in the hot-plate 
test. Spironolactone also displayed prono-
ciceptive effect on electrically-induced 
pain. In contrast, spironolactone displayed 
an antinociceptive effect upon the capsai-
cin-induced chemogenic pain. Spironolac-
tone also inhibited the behavioral nocicep-
tive effects evoked by injection of acetic 
acid into the peritoneal cavity of mice, a 
widely used model for visceral pain. The 
effect of the oral administration of the drug 
on visceral pain responses, however, was 
not dose-dependant.  
The tail-flick response is considered to 
be a spinal reflex whereas the hotplate test 
involves supraspinal processing (Sinclair et 
al., 1988). For the tail electric stimulation, 
the motor and simple vocalization re-
sponses have been suggested to be organ-
ized at the spinal cord and caudal brainstem 
levels, respectively (Hoffmeister, 1968). 
Spironolactone thus is likely to act at spinal 
and supraspinal sites to modulate pain re-
sponses. The presence of mineralocorticoid 
receptors in some areas within the brain 
such as the hippocampus and within the nu-
cleus of the solitary tract (Krozowski and 
Funder, 1983; Geerling et al., 2006) have 
been demonstrated. Mineralocorticoid ef-
fects in the brain include the control of car-
diac vagal activity (Fletcher et al., 2004), 
induction of salt appetite (Zhang et al., 
1993), sympathetic excitation and blood 
pressure elevation (Gomez-Sanchez, 1997; 
Wang et al., 2003; Zhang et al., 2006). 
Studies suggest that aldosterone, originating 
in the periphery and acting on brain MR, 
activates brain MAPK pathways to produce 
sympatho-excitatory responses (Geerling et 
al., 2006). In contrast, central MR blockade 
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has been shown to reduce sympathetic drive 
(Francis et al., 2001). Significant changes in 
adrenal and blood aldosterone levels were 
seen 2.5 min after acute nociception 
(Belyakova and Mendzheritskii, 2006). Fur-
thermore, in intact rats, the brain concentra-
tion of aldosterone reflected that in the 
plasma and aldosterone was consistently 
found in the brains of adrenalectomized 
rats, suggesting that the small amounts of 
aldosterone synthesized in the brain could 
provide a local ligand for autocrine or 
paracrine activation of the MR (Gomez-
Sanchez et al., 2005).  
The effect of spironolactone on pain re-
sponses are not clear, but it has been shown 
that, aldosterone micropellets implanted in 
amygdala led to increased visceromotor be-
havioral responses to colorectal distention. 
More spinal neurons had spontaneous activ-
ity and exhibited low thresholds for excit-
ability responses to colorectal distention 
and these responses were higher magnitude 
and longer duration. Thus MR-mediated 
mechanisms are likely to be involved in de-
scending pathways into lumbosacral spinal 
neurons that induce colorectal hypersensi-
tivity to luminal distention (Qin et al., 
2003). Aldosterone implants into the amyg-
dala increased the number of abdominal 
muscle contractions in response to all levels 
of colorectal distension. MR mediated-
mechanisms thus induce visceral hypersen-
sitivity via processes originating in the 
amygdala (Myers and Greenwood-Van 
Meerveld, 2010). Blockade of central MRs 
by spironolactone is therefore expected to 
reduce visceral pain responses. Spironolac-
tone also possesses potent anti-
inflammatory and immune modifying prop-
erties (Francis et al., 2003; Hansen et al., 
2004; Sonder et al., 2006) which could be 
relevant to its visceral pain inhibiting prop-
erties shown in the present study. The 
model of inflammatory pain evoked by ace-
tic acid injection into the peritoneal cavity 
involves the local release of prostaglandins 
in the peritoneal cavity (Berkenkopf and 
Weichman, 1988). It can be inhibited by the 
administration of cyclo-oxygenase inhibi-
tors (Santos et al., 1998), as well as by 
drugs acting on central monoaminergic neu-
rotransmission, e. g., fluoxetine (Abdel-
Salam, 2005), or by morphine (Baamonde 
et al., 1989). We further attempted to eluci-
date mechanism by which spironolactone 
alleviate visceral pain. The analgesic re-
sponse to spironolactone was partially di-
minished by administration the alpha-2 re-
ceptor antagonist yohimbine, suggesting 
that alpha (2)-adrenoceptor-mediated 
mechanism could be involved. Spinal 
noradrenergic systems participate in pain-
relieving mechanisms, and the alpha-2 re-
ceptor agonists clonidine and dexme-
tomidine are effective analgesics and poten-
tiate the analgesic effects of morphine 
(Chen et al., 2009; Gulati et al., 2009). Spi-
ronolactone at doses, which caused effec-
tive visceral anti-nociception, did not im-
pair mouse performance evaluated by the 
rotarod test, thus ruling out the confounding 
influence of a possible sedative effect. Sig-
nificantly impaired rotarod performances 
occurred only with in contrast, higher doses 
of 40 and 80 mg/kg of the drug.  
Catalepsy occurs following high dopa-
mine D2 receptor blockade by the typical 
antipsychotic drug haloperidol. The halo-
peridol-induced catalepsy is a behavioral 
predictor of extrapyramidal symptoms li-
ability (Farde et al., 1992; Hoffman and 
Donovan, 1995). In the present study, spi-
ronolactone increased the duration of 
haloperidol-induced catalepsy in a dose-
related manner. Symptoms of Parkinson’s 
disease are mainly related to a progressive 
degeneration of dopamine producing neu-
rons in the substantia nigra pars compacta 
(SNc) and to a lesser extent in the ventral 
tegmental area (VTA), the most prominent 
dopamine nuclei in the brain (Torack and 
Morris, 1992; Hirsch et al., 2003). There is 
no evidence yet that spironolactone affects 
dopamine release. But, the nucleus of the 
solitary tract contains a subpopulation of 
neurons which are uniquely sensitive to al-
dosterone and send minor axonal projec-
tions to the midbrain VTA (Geerling et al., 
2006). The latter is a cluster of neurons in 
the midbrain tegmentum located just medial 
to the SNc, implicated mainly in attention, 
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memory, reward and motivation (Nowak et 
al., 2000; Howard et al., 2007; de Oliveira 
et al., 2009), but is involved in some motor 
behaviors as well (Stinus et al., 1980; Hull 
et al., 1991; Trojniar and Klejbor, 1999). 
This raises an intriguing question whether 
central aldosterone might influence the ac-
tivity of dopaminergic neurons of this struc-
ture and thus is involved in the control of 
movements. Studies suggested that spiro-
nolactone act centrally to affect mood and 
behavior (Hendler, 1978). Balanced activa-
tion of MRs and GRs is also necessary for 
optimal memory function in humans 
(Tytherleigh et al., 2004) and spironolac-
tone impairs cognitive function by signifi-
cantly impairing selective attention and de-
layed recall of visuospatial memory (Otte et 
al., 2007). Studies also indicated that in-
creased neuronal MR has neuroprotective 
effects. Transgenic mice over expressing 
MR in forebrain had significantly reduced 
neuronal death, improved spatial memory 
retention, and reduced anxiety following 
transient cerebral global ischemia compared 
to wild-type littermates. This effect was in-
dependent on alterations in basal or post 
stress HPA axis function or in arterial blood 
pressure (Lai et al., 2007). Consequently it 
might be hypothesized that blockade of cen-
tral MR receptors could have adverse ef-
fects on neuronal integrity in vulnerable 
regions.  
In conclusion, systemic injections of 
spironolactone increased pain behavior in 
models of thermal, chemogenic and electri-
cally-induced pain, whereas visceral pain 
was reduced by the drug. The effect of spi-
ronolactone on motor symptoms in patients 
with Parkinson’s disease or on antipsy-
chotic drug therapy needs further investiga-
tion. 
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